Skip to main content

Table 3 Effects of weight loss on QOL and clinical outcomes (ancillary analyses)

From: A randomized trial of a lifestyle intervention in obese endometrial cancer survivors: quality of life outcomes and mediators of behavior change

Variables

Baseline

3 mos

6 mos

12 mos

Group effect P*

Primary QoL outcome

     

FACT-G

    

0.26

   WL

81.4 (14.0)

83.5 (15.7)

84.8 (14.7)

82.3 (15.4)

 

   WG

78.9 (11.7)

78.1 (13.3)

79.8 (12.6)

80.1 (13.8)

 

Secondary QoL outcomes

     

Physical well-being (0–28)

    

0.79

   WL

24.7 (3.3)

24.5 (4.6)

24.7 (4.7)

24.2 (4.8)

 

   WG

23.1 (3.0)

22.5 (4.0)

23.5 (3.7)

22.8 (3.5)

 

Functional well-being (0–28)

     

   WL

21.9 (5.6)

22.8 (5.3)

23.3 (5.0)

21.9 (6.1)

0.65

   WG

20.5 (5.2)

21.2 (5.8)

20.8 (5.4)

21.2 (6.2)

 

Emotional well-being (0–24)

     

   WL

18.2 (4.3)

20.0 (4.1)

20.0 (4.3)

19.5 (4.2)

0.02

   WG

18.9 (4.0)

18.4 (4.2)

18.9 (4.2)

19.3 (4.1)

 

Social/family well-being (0–28)

     

   WL

16.6 (3.2)

16.2 (3.4)

17.0 (2.8)

16.7 (2.8)

0.98

   WG

16.4 (3.0)

16.0 (3.0)

16.5 (2.9)

16.8 (3.2)

 

Fatigue (0–52)

     

   WL

39.0 (10.2)

41.6 (10.5)

41.4 (12.1)

42.0 (10.5)

0.07

   WG

36.9 (9.3)

36.3 (10.5)

37.3 (10.7)

36.9 (9.5)

 

Endometrial subscale (0–64)

     

   WL

54.3 (6.6)

54.3 (7.7)

55.2 (8.1)

55.5 (6.9)

0.55

   WG

52.8 (5.1)

52.7 (6.2)

53.1 (5.7)

53.3 (5.9)

 

WEL

     

Negative emotions (0–36)

    

< 0.01

   WL

16.7 (10.9)

24.3 (10.5)

25.6 (9.3)

25.6 (9.7)

 

   WG

20.0 (10.3)

22.4 (9.5)

20.5 (3.3)

20.6 (9.8)

 

Food Availability (0–36)

    

0.03

   WL

16.5 (10.4)

24.0 (9.6)

23.8 (9.9)

24.4 (10.4)

 

   WG

19.5 (8.3)

22.8 (9.0)

20.7 (9.4)

21.4 (9.4)

 

Social pressure (0–36)

    

0.20

   WL

25.2 (9.2)

28.4 (7.5)

28.1 (7.5)

29.1 (7.2)

 

   WG

22.7 (8.1)

26.1 (8.0)

23.9 (8.2)

25.2 (7.6)

 

Positive activities (0–36)

    

0.10

   WL

23.0 (7.9)

27.5 (6.2)

27.5 (5.3)

27.8 (5.0)

 

   WG

25.1 (6.5)

27.5 (6.9)

25.4 (7.0)

27.4 (4.6)

 

Physical discomfort (0–36)

     

   WL

25.5 (9.2)

29.6 (7.0)

30.0 (6.9)

30.8 (7.1)

0.01

   WG

27.0 (7.4)

28.1 (6.5)

26.9 (6.2)

28.0 (5.7)

 

Total (0–180)

    

<0.01

   WL

106.9 (37.4)

133.8 (36.0)

135.0 (33.8)

137.6 (33.9)

 

   WG

114.3 (35.5)

126.9 (33.9)

117.4 (34.4)

122.6 (31.4)

 

Beck depression inventory

     

   WL

9.3 (7.0)

-

-

7.0 (6.5)

0.03

   WG

10.9 (8.8)

-

-

9.7 (7.9)

0.14

TFEQ

     

Restraint (0–21)

     

   WL

10.1 (4.5)

-

-

12.9 (4.2)

<0.01

   WG

10.2 (5.4)

-

-

10.3 (5.3)

0.74

Disinhibition (0–16)

     

   WL

7.8 (3.0)

-

-

6.9 (3.3)

0.05

   WG

8.1 (4.1)

-

-

8.4 (4.1)

0.48

Hunger (0–14)

     

   WL

6.1 (3.8)

-

-

5.1 (2.5)

0.21

   WG

5.3 (3.1)

-

-

5.1 (3.1)

0.51

  1. Data are presented as the mean (standard deviation).
  2. WL, n = 21; WG, n = 24
  3. * p value for repeated measures ANOVA with baseline measurement as covariate and 3, 6 and 12 months as outcomes or paired samples t-test (eating inventory and Beck depression inventory)
  4. Abbreviations: QoL, quality of life; FACT-G, Functional Assessment of Cancer Therapy-General; SF-36, Short-form Medical Outcomes Survey; BDI, Beck Depression Inventory; WEL, weight efficacy lifestyle; TFEQ, three-factor eating questionnaire; BMI, body mass index